101. Racial disparities in the survival of patients with indolent <scp>non‐Hodgkin</scp> lymphomas in the United States
- Author
-
Daniela Spies, Ana C. Xavier, Narendranath Epperla, and John L Vaughn
- Subjects
Adult ,Male ,medicine.medical_specialty ,Follicular lymphoma ,Black People ,Race and health ,White People ,Lymphoplasmacytic Lymphoma ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Internal medicine ,medicine ,Humans ,Mortality ,American Indian or Alaska Native ,Survival analysis ,Aged ,Relative survival ,business.industry ,Lymphoma, Non-Hodgkin ,Hazard ratio ,Waldenstrom macroglobulinemia ,Health Status Disparities ,Hematology ,Middle Aged ,Alaskan Natives ,medicine.disease ,Survival Analysis ,United States ,030220 oncology & carcinogenesis ,Pacific islanders ,Female ,business ,030215 immunology - Abstract
There is a paucity of data regarding racial disparities in the survival of patients with indolent non-Hodgkin lymphomas (iNHL) in the contemporary time-period. Hence, we sought to determine whether racial disparities exist in the survival of patients with iNHLs in the US. We included 68,059 adult patients with follicular lymphoma (FL, n=41,943), marginal zone lymphoma (MZL, n=22,485), and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM, n=3,631) who were diagnosed in the US between 2000-2017. Race was categorized as White, Black, Asian/Pacific Islander, or American Indian/Alaska Native (API/AI). The primary outcome was relative survival (RS), which was estimated using flexible parametric survival models. RS estimates varied according to race and disease histology but were consistently lower for racial minorities, including those diagnosed during the most recent 5-year time-period of 2012-2017. On multivariable analysis for RS, Black patients with FL had a 32% higher excess mortality rate compared to White patients [adjusted excess hazard ratio (aEHR), 1.32; 95% CI, 1.15-1.51; P
- Published
- 2021
- Full Text
- View/download PDF